CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 142 enrolled
Drug / intervention
Discontinue alendronatedrug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Postmenopausal women with ≥2 years since menopause
  • ✓Men aged >50 years
  • ✓Alendronate treatment for ≥5 years
  • ✓BMD T-score total hip >-2.5
Key exclusion· 8
  • ✕Any low-energy fracture (except fingers, toes, skull) within 5 years during alendronate treatment
  • ✕Low-energy vertebral fracture at any time
  • ✕Low-energy hip fracture at any time
  • ✕Ongoing glucocorticoid treatment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03051620
NCT03051620N/ACompleted
CompareCT.gov

Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate

Aarhus University Hospital·observational·Posted Feb 14, 2017·Updated Mar 18, 2021

In Brief

An observational study evaluating Discontinue alendronate for Osteoporosis. Completed, enrolled 142 participants across 1 site.

Detailed Summary

The study is a cohort study comprising 136 patients with osteoporosis stopping treatment with alendronate. The study will contribute with new knowledge about biochemical markers of bone turnover as predictors of bone loss after stopping treatment with alendronate.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesDenmark
CollaboratorsUniversity of Aarhus

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 14, 2017
Enrollment StartFeb 1, 2017
Primary CompletionJan 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.4 years ago

Interventions

Discontinue alendronatedrug

136 patients with osteoporosis stopping treatment with alendronate.